HER2 gene amplification may have impact on CDK 4/6 inhibitor-therapy effectiveness in patients with metastatic breast cancer. Read More ›

Pooled analysis of the MONALEESA-2, -3, and -7 clinical trials finds elderly patients have survival benefits from treatment with ribociclib plus endocrine therapy. Read More ›

Focus group analysis of stakeholders in metastatic breast cancer treatment finds a need for accessible and patient-friendly terminology in metastatic breast cancer treatment-making discussions. Read More ›

The use of CDK4/6 inhibitors following radiotherapy demonstrated to be safe and effective in patients with HR+/HER2– advanced breast cancer who develop brain metastases. Read More ›

Recent retrospective study finds that receiving CDK4/6 inhibitor plus endocrine therapy improves progression-free survival in patients with HR+/HER2– metastatic breast cancer. Read More ›

Page 2 of 2

Conference Correspondent Coverage is Brought to You by the Publishers of:
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management

Learn more about our family of publications.

View Our Publications